Zylox-Tonbridge and GL Capital Announce Strategic Investment in LifeTech Scientific to Build a Leading Vascular and Structural Heart Intervention Platform

Markets PR Newswire By PR Newswire 06 Nov 2026 17:40 1 min read
Zylox-Tonbridge and GL Capital Announce Strategic Investment in LifeTech Scientific to Build a Leading Vascular and Structural Heart Intervention Platform

HANGZHOU, China, Nov. 6, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190) ("Zylox-Tonbridge") today announced a strategic investment in LifeTech Scientific Corporation (HKEX: 1302) ("LifeTech"), in partnership with GL Capital, marking a significant step...

Covered in this story

Call it yourself

No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on NOV →

Dalsna Finance is currently tracking 112 stories mentioning NOV, the earliest published 7 Oct 2025.

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.